Cargando…

Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors

BACKGROUND: Definitive diagnosis of primary central nervous system lymphoma (PCNSL) requires invasive surgical brain biopsy, causing treatment delays. In this paper, we identified and validated tumor-specific markers that can distinguish PCNSL from other CNS tumors in tissues. In a pilot study, we t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Downs, Bradley M., Ding, Wanjun, Cope, Leslie M., Umbricht, Christopher B., Li, Wenge, He, Huihua, Ke, Xiaokang, Holdhoff, Matthias, Bettegowda, Chetan, Tao, Weiping, Sukumar, Saraswati
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097855/ https://www.ncbi.nlm.nih.gov/pubmed/33952317 http://dx.doi.org/10.1186/s13148-021-01091-9

Ejemplares similares

New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL)
por: Gomes Candido Reis, Diego, et al.
Publicado: (2021)

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma
por: Wendler, Julia, et al.
Publicado: (2022)

Treatment outcome and prognostic factors in PCNSL
por: Niparuck, Pimjai, et al.
Publicado: (2019)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?
por: Cope, Leslie M., et al.
Publicado: (2014)

Primary central nervous system lymphoma (PCNSL) mimicking a falx meningioma with increasingly massive intracerebral hemorrhage
por: Tomita, Yusuke, et al.
Publicado: (2023)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

GEN-13 PAIRED MUTATIONAL ANALYSIS IN SECONDARY NERVOUS SYSTEM LYMPHOMA AND PCNSL SYSTEMIC RELAPSE REVEALS DRIVER MUTATION CANDIDATES IN THE CENTRAL NERVOUS SYSTEM
por: Sasaki, Nobuyoshi, et al.
Publicado: (2022)

Different imaging patterns of PCNSL and IVL: a case report
por: Jeon, Seung-Ho, et al.
Publicado: (2019)

Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL
por: Baraniskin, Alexander, et al.
Publicado: (2021)

Primary Central Nervous System Lymphoma (PCNSL): Analysis of Treatment by Gamma Knife Radiosurgery and Chemotherapy in a Prospective, Observational Study
por: Alvarez-Pinzon, Andres M, et al.
Publicado: (2016)

Risk factors for death and temporal trends in overall survival in patients with AIDS-associated primary central nervous system lymphoma (AIDS-PCNSL)
por: Uldrick, Thomas S, et al.
Publicado: (2012)

PB2356: OUTCOMES OF PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL) WHO UNDERWENT TREATMENT WITH DEANGELIS, MATRIX, AND PRIMAIN PROTOCOL.: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Richardson, Michelle, et al.
Publicado: (2023)

GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL
por: Takashima, Yasuo, et al.
Publicado: (2020)

Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer
por: Fackler, Mary Jo, et al.
Publicado: (2022)

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
por: Calimeri, Teresa, et al.
Publicado: (2022)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
por: Schreck, Karisa C., et al.
Publicado: (2019)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies
por: Holdhoff, Matthias, et al.
Publicado: (2020)

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
por: Kim, Therasa, et al.
Publicado: (2018)

Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study
por: Kuitunen, Hanne K., et al.
Publicado: (2023)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

ML-5 THE TRANSITION OF THE TREATMENT OF 60 PCNSL CASES AT OUR INSTITUTION AND CLINICAL CONSIDERATIONS
por: Yoshitake, Hidenobu, et al.
Publicado: (2022)

ML-4 POLICY CHANGE TO PCNSL TREATMENT LED BY HEMATOLOGY, AND INITIAL TREATMENT RESULTS
por: Hashiba, Tetsuo, et al.
Publicado: (2022)

Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL
por: MITOBE, Yuta, et al.
Publicado: (2023)

Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group
por: Steffanoni, Sara, et al.
Publicado: (2022)

ML-13 The primary treatment outcomes and future problems of PCNSL elderly patients in our institute
por: Kambe, Atsushi, et al.
Publicado: (2020)

Detecting aberrant DNA methylation in Illumina DNA methylation arrays: a toolbox and recommendations for its use
por: Downs, Bradley M., et al.
Publicado: (2023)

DNA methylation markers predict recurrence-free interval in triple-negative breast cancer
por: Fackler, Mary Jo, et al.
Publicado: (2020)

ML-14 Re-challenge and maintenance therapy of methotrexate for elderly PCNSL patients with low scored KPS
por: Yamaguchi, Takashi, et al.
Publicado: (2020)

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib
por: Sasaki, Nobuyoshi, et al.
Publicado: (2021)

Expression and Clinical Significance of Th1/Th2/Th17 Cytokines and Lymphocyte Subsets in PCNSL
por: Bian, Haiyan, et al.
Publicado: (2022)

Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
por: Kharkar, Prashant S.
Publicado: (2014)

High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers
por: Ma, Jingjing, et al.
Publicado: (2023)

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
por: Ghose, Arup K., et al.
Publicado: (2011)

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)
por: Swinnen, Lode J., et al.
Publicado: (2017)

Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)
por: Nagano, Masahiro, et al.
Publicado: (2019)

Improving the Classification of PCNSL and Brain Metastases by Developing a Machine Learning Model Based on (18)F-FDG PET
por: Cui, Can, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3ippsdf2sugikudeg2ofrbhto8